IsisCB Explore

Article ID: CBB016946522

“Ready for What?”: Timing and Speculation in Alzheimer’s Disease Drug Development (May 2022)

Natassia F. Brenman (Author)
Richard Milne (Author)

Science, Technology and Human Values
Volume: 47
Issue: 3
Pages: 597-622

DOI: 10.1177/01622439211007196

URI: https://doi.org/10.1177/01622439211007196

Outside Links

WorldCat

Google Scholar

JSTOR

Academia.edu

Medicine Alzheimer's disease Technoscience; science and technology studies Ethics Drug testing Pharmaceutical industry Clinical trials 21st century

“Readiness cohorts” are an innovation in clinical trial design to tackle the scarcity of time and people in drug studies. This has emerged in response to the challenges of recruiting the “right” research participants at the “right time” in the context of precision medicine. In this paper, we consider how the achievement of “readiness” aligns temporalities, biologies, and market processes of pharmaceutical innovation: how the promise of “willing bodies” in research emerges in relation to intertwined economic and biological time imperatives. Drawing on long-term engagement with the field of Alzheimer’s disease prevention and interviews with researchers from academia and the pharmaceutical industry, we describe the discursive construction and practical arrangement of readiness. This paper contributes to understandings of temporal specificity, or “timing,” within prevention research and casts critical light on the way this specificity—the threshold for “trial readiness”—relates to an opaque and highly speculative drug development pipeline. Extending the study of biomedical potential, as that which holds promise but may not yet exist, we consider how absences operate in adaptive trials. By highlighting these absences (“ready for what?”), we outline an opportunity for socio-ethical research to intervene in the speculative gaps of drug development.

...More

Citation URI

https://data.isiscb.org/isis/citation/CBB016946522/

Citations Indexes

Similar Citations

Article Jill A. Fisher; (March 2015)
Feeding and Bleeding: The Institutional Banalization of Risk to Healthy Volunteers in Phase I Pharmaceutical Clinical Trials (/isis/citation/CBB066653855/)

Article Julia Swallow; Alexandra Hillman; (April 2019)
Fear and anxiety: Affects, emotions and care practices in the memory clinic (/isis/citation/CBB055124638/)

Article Petty, JuLeigh; Heimer, Carol A.; (2011)
Extending the rails: How research reshapes clinics (/isis/citation/CBB060848255/)

Article Clay Davis; (December 2020)
Homo adhaerens: Risk and adherence in biomedical HIV prevention research (/isis/citation/CBB559629478/)

Article Brives, Charlotte; (2013)
Identifying ontologies in a clinical trial (/isis/citation/CBB362744143/)

Article Andrea M. Bertotti; Skye A. Miner; (April 2019)
Constructing contentious and noncontentious facts: How gynecology textbooks create certainty around pharma-contraceptive safety: Research Note (/isis/citation/CBB188878802/)

Article Lyle Fearnley; (September 2020)
Viral Sovereignty or Sequence Etiquette? Asian Science, Open Data, and Knowledge Control in Global Virus Surveillance (/isis/citation/CBB925083175/)

Book Shirley Hsiao-Li Sun; (2017)
Socio-economics of Personalized Medicine in Asia (/isis/citation/CBB224387222/)

Article Natalie B. Aviles; (September 2018)
Situated Practice and the Emergence of Ethical Research: HPV Vaccine Development and Organizational Cultures of Translation at the National Cancer Institute (/isis/citation/CBB981072036/)

Article Sky Edith Gross; Shai Lavi; Hagai Boas; (2019)
Medicine, Technology, and Religion Reconsidered: The Case of Brain Death Definition in Israel (/isis/citation/CBB228629534/)

Article Margaret E. MacDonald; (March 2021)
Misoprostol: The Social Life of a Life-saving Drug in Global Maternal Health (/isis/citation/CBB680292467/)

Article Sara L. Ackerman; Katherine Weatherford Darling; Sandra Soo-Jin Lee; (March 2016)
Accounting for Complexity: Gene–environment Interaction Research and the Moral Economy of Quantification (/isis/citation/CBB257526872/)

Article Christine Hauskeller; (March 2020)
Care Ethics and Care Contexts: Contributions from Feminist Philosophy (/isis/citation/CBB147695752/)

Article Hoeyer, Klaus L.; Jensen, Anja M. B.; (August 2013)
Transgressive ethics: Professional work ethics as a perspective on ‘aggressive organ harvesting’ (/isis/citation/CBB490167143/)

Article Arne Pollock; (March 2015)
On the Suspended Sentences of the Scott Sisters: Mass Incarceration, Kidney Donation, and the Biopolitics of Race in the United States (/isis/citation/CBB568362575/)

Article Salla Sariola; Roger Jeffery; Amar Jesani; Gerard Porter; (2019)
How Civil Society Organisations Changed the Regulation of Clinical Trials in India (/isis/citation/CBB527783392/)

Book Fisher, Jill; (2009)
Medical Research for Hire: The Political Economy of Pharmaceutical Clinical Trials (/isis/citation/CBB000953570/)

Article Jeremy A. Greene; (2017)
Therapeutic Proofs and Medical Truths: The Enduring Legacy of Early Modern Drug Trials (/isis/citation/CBB978757359/)

Article María González-Moreno; Cristian Saborido; David Teira; (2015)
Disease-mongering through clinical trials (/isis/citation/CBB362630000/)

Article Natali Valdez; (2022)
The Politics of Postgenomic Reproduction: Exploring Pregnant Narratives from within a Clinical Trial (/isis/citation/CBB617544692/)

Comments

{{ comment.created_by.username }} on {{ comment.created_on | date:'medium' }}